½ÃÀ庸°í¼­
»óǰÄÚµå
1771312

¼¼°èÀÇ Drug Discovery Ç÷§Æû ½ÃÀå : ¾÷°è µ¿Çâ ¹× ¿¹Ãø - µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú À¯Çüº°, ºÐÀÚ À¯Çüº°, ÁÖ¿ä Áö¿ªº°

Drug Discovery Platforms Market: Industry Trends and Global Forecasts - Distribution by Type of Display Library Technology, Type of Molecule and Key Geographical Regions

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Roots Analysis | ÆäÀÌÁö Á¤º¸: ¿µ¹® 220 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Drug Discovery Ç÷§Æû ½ÃÀå : °³¿ä

¼¼°èÀÇ Drug Discovery Ç÷§Æû ½ÃÀå ±Ô¸ð´Â ¿ÃÇØ 1¾ï 3,900¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÀÌ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È 13.4%ÀÇ CAGR·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­ ¹× ±âȸ ºÐ¼®Àº ´ÙÀ½ ¸Å°³º¯¼ö·Î ¼¼ºÐÈ­µË´Ï´Ù.

µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú À¯Çüº°

  • ÆÄÁö µð½ºÇ÷¹ÀÌ
  • È¿¸ð µð½ºÇ÷¹ÀÌ
  • ±âŸ

ºÐÀÚ À¯Çüº°

  • Ç×ü
  • ÆéƼµå
  • ±âŸ

ÁÖ¿ä Áö¿ªº°

  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç

¼¼°èÀÇ Drug Discovery Ç÷§Æû ½ÃÀå : ¼ºÀå°ú µ¿Çâ

Drug Discovery´Â Ç×»ó ½Ã°£ÀÌ °É¸®´Â °úÁ¤ÀÔ´Ï´Ù. ½ÇÁ¦·Î ÀǾàǰÀ» »ó¾÷ÀûÀ¸·Î Ãâ½ÃÇϱâ À§Çؼ­´Â Æò±Õ 10-15³âÀÇ ¼¼¿ù°ú 40-100¾ï ´Þ·¯ »ó´çÀÇ ÅõÀÚ°¡ ÇÊ¿äÇÕ´Ï´Ù. Drug Discovery °³¹ß °úÁ¤¿¡´Â Ÿ±ê ¼±Åà ¹× °ËÁõ, È÷Æ® È­ÇÕ¹° âÃâ, ¸®µå È­ÇÕ¹° ÃÖÀûÈ­, ÇÁ·ÎÅäÄÝ Æ¯¼º Æò°¡ µî ´Ù¾çÇÑ ´Ü°è°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ ´Ü°è Áß È÷Æ®(À¯È¿¼ºÀÌ È®ÀÎµÈ »ý¹°ÇÐÀû Ç¥Àû¿¡ ´ëÇÑ ÀáÀçÀûÀÎ ÀǾàǰ Èĺ¸)ÀÇ Ã¢ÃâÀº Áö±ØÈ÷ ÀÚ¿ø Áý¾àÀûÀÎ ÇÁ·Î¼¼½ºÀÔ´Ï´Ù. ¹Ù¸®µ¥ÀÌÆ® µÈ Ÿ°Ù¿¡ ´ëÇÑ È÷Æ® È­ÇÕ¹°ÀÇ Ã¢Ãâ¿¡´Â Æò±ÕÀûÀ¸·Î ¾à 18°³¿ùÀÌ ¼Ò¿äµÇ´Â °ÍÀº ƯÇÊÇÒ ¸¸ÇÕ´Ï´Ù. ÀÌ¿¡ ´õÇØ Drug DiscoveryÀÇ È÷Æ® »ý¼º¿¡¼­ ¸®µå È­ÇÕ¹° µ¿Á¤ ´Ü°è¿¡¼­´Â ¾à 25%ÀÇ È®·ü·Î ½ÇÆÐÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿ì·Á¿¡ ´ëóÇϱâ À§ÇØ °³¹ßÀÚ´Â ±âÁ¸ÀÇ ±â¹ý¿¡¼­ ½Å±Ô Drug Discovery Ç÷§Æû »ç¿ëÀ¸·Î ÁßÁ¡À» ¿Å±â°í ÀÖ½À´Ï´Ù.

Drug Discovery Platforms Market-IMG1

¼ö³â¿¡ °ÉÃÄ ½ÇÇà °¡´ÉÇÑ Ä¡·á ¸®µå¸¦ »ý»êÇÏ´Â ¼ö¸¹Àº ±â¼ú°ú Á¢±Ù¹ýÀÌ È®¸³µÇ¾î ¿Ô½À´Ï´Ù. ÇÏÀ̺긮µå µµ¸¶ ±â¼ú, B¼¼Æ÷ Ŭ·Î´×, Æ®·£½ºÁ¦´Ð µ¿¹° ±â¹Ý ±â¼ú, in vitro µð½ºÇ÷¹À̹ý, Æ÷À¯·ù, È¿¸ð, ¼¼±Õ ¼¼Æ÷¸¦ Æ÷ÇÔÇÑ ¼¼Æ÷ Ç¥¸é µð½ºÇ÷¹ÀÌ ±â¼ú µîÀÔ´Ï´Ù. Çö´ë ÀÇÇÐ ¿¬±¸¿¡¼­ µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸®´Â ´Ù¾çÇÑ ½Å±Ô Ä¡·áÁ¦ »ý¼º¿¡ È¿°úÀûÀ¸·Î ÀÌ¿ëµÇ°í ÀÖÀ¸¸ç ±âÁ¸ ¾àÁ¦ ½ºÅ©¸®´×¹ý¿¡ ºñÇØ ¸î °¡Áö ÀÌÁ¡ÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌÁ¡¿¡´Â ´ë±Ô¸ð ÇÏÀÌ Ã³¸®·® ½ºÅ©¸®´×À» °¡´ÉÇÏ°Ô ÇÏ´Â °Í, ½ÇÇà °¡´ÉÇÑ ¸®µå È­ÇÕ¹°À» µ¿Á¤ÇÒ ¶§ ´Ù¾ç¼ºÀ» ÃÊ·¡ÇÏ´Â °Í, ÀÌ Á¢±Ù¹ý¿¡ ÀÇÇØ ¹ß°ßµÈ ¾à¸®ÇÐÀû Èĺ¸ È­ÇÕ¹°¿¡ ´ëÇÑ ¸é¿ª ¹ÝÀÀÀÇ À§ÇèÀ» ÁÙÀÌ´Â °Í µîÀÌ Æ÷ÇԵ˴ϴÙ. µð½ºÇ÷¹ÀÌ ±â¼úÀº ¼­¼­È÷ Drug Discovery °úÁ¤¿¡¼­ Å« ¹ßÀüÀ» ÃËÁøÇØ ¿Ô½À´Ï´Ù. ±× °á°ú Drug Discovery Ç÷§Æû ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È °­·ÂÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°èÀÇ Drug Discovery Ç÷§Æû ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

ÀÌ º¸°í¼­´Â ¼¼°èÀÇ Drug Discovery Ç÷§Æû ½ÃÀåÀÇ ÇöÀç »óŸ¦ Á¶»çÇϰí ÀáÀçÀûÀÎ ¼ºÀå ±âȸ¸¦ È®ÀÎÇϰí ÀÖ½À´Ï´Ù. º» º¸°í¼­ÀÇ ÁÖ¿ä Á¶»ç °á°ú´Â ´ÙÀ½°ú °°½À´Ï´Ù.

  • ¼¼°èÀÇ ´Ù¾çÇÑ Áö¿ª¿¡ °ÅÁ¡À» µÎ°í ÀÖ´Â ¿©·¯ ±â¾÷ÀÌ µ¶ÀÚÀûÀÎ µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼úÀ» °¡Áö°í ÀÖÀ¸¸ç, ´Ù¾çÇÑ À¯ÇüÀÇ ¾à¸®ÇÐÀû ºÐÀÚÀÇ Å½»öÀ» À§ÇÑ Á¦ÈÞ ¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù°í ÁÖÀåÇϰí ÀÖ½À´Ï´Ù.
  • ÆÄÁö µð½ºÇ÷¹ÀÌ(-70%)´Â °¡Àå ¼º°øÀûÀÎ µð½ºÇ÷¹ÀÌ ±â¼ú Áß Çϳª·Î °£Áֵ˴ϴÙ. ÀÌÇØ°ü°èÀÚµéÀº È¿¸ð¿Í Æ÷À¯·ù ¼¼Æ÷¸¦ ±â¹ÝÀ¸·Î ÇÏ´Â °Í°ú °°Àº ´Ù¸¥ À¯»çÇÑ Á¢±Ù¹ýµµ ¿¬±¸Çϰí ÀÖ½À´Ï´Ù.
  • µð½ºÇ÷¹ÀÌ ±â¼úÀº ´ë±Ô¸ð »ý»ê, ¹è¿­¿¡ ´ëÇÑ Á÷Á¢ ¾×¼¼½º, ´Ù¾çÇÑ Å¬·ÐÀÇ ½ºÅ©¸®´× ¿ëÀ̼º µî ¸î °¡Áö ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù.
  • µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸®´Â °íÁ¤È­ Ç׿ø¿¡ ´ëÇÑ Ç×üÀÇ ½ÃÇè°ü³» ¼±Åà ¹× ¸é¿ª¿ø¼ºÀÌ ³·Àº Ç¥Àû¿¡ ´ëÇÑ Ç×üÀÇ ´Ü¸®¿¡ »ç¿ëµÉ ¼ö ÀÖ½À´Ï´Ù.
  • ¾à¹° È常¦ »ý»êÇϱâ À§ÇØ, µ¿¹°ÀÇ ¸é¿ª°èÀÇ Á¦¾îÇÏ¿¡ Á¶ÀÛÇÒ ¼ö ÀÖ´Â º¹¼öÀÇ µ¿¹° ¸ðµ¨À» ¼±Åÿ¡ ÀÌ¿ëÇÏ´Â ÁøÃâ±â¾÷µµ ÀÖ½À´Ï´Ù.
  • ÀÌ ºÐ¾ß¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ´Ù´Â °ÍÀº Á¦ÈÞ È°µ¿ÀÇ È°¼ºÈ­¿¡¼­µµ ºÐ¸íÇÕ´Ï´Ù. »ç½Ç, Áö³­ 2³â µ¿¾È ´Ù¾çÇÑ À¯ÇüÀÇ µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼úÀ» Æ÷ÇÔÇÑ Á¦ÈÞ°¡ ÃÖ´ë ¸î °³ ¸Î¾îÁ® ÀÖ½À´Ï´Ù.
Drug Discovery Platforms Market-IMG2
  • ±âÁ¸ ±â¾÷°ú ½ÅÈï ±â¾÷ ¸ðµÎ ¿©·¯ ÆÄÆ®³Ê½ÊÀ» ¸Î°í ÀÖÀ¸¸ç, ´ëºÎºÐÀº ¿¬±¸ ¹× Ä¡·á ¸ñÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ´Â ±â¼ú ¶óÀ̼±½º °è¾à(-45%)ÀÔ´Ï´Ù.
  • ´Ù¾çÇÑ À¯ÇüÀÇ ½ÃÇè°ü³» µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸®¿Í À̸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ±â¼ú, ±×¸®°í ¾à¹° ¹× Ä¡·á¹ý¿¡¼­ÀÇ »ç¿ë¹ýÀ» ¼³¸íÇÏ´Â Á¢±Ù¹ý°ú °ü·ÃµÈ °úÇÐÀû ¹®ÇåÀÇ ÃâÆÇÀÌ ÇöÀúÇÏ°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
  • Áö³­ 2³â°£, µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú°ú Drug Discovery¿¡ ´ëÇÑ ¿ëµµ¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸ ³í¹®À» Æ÷ÇÔÇÑ ÃâÆÇ¹°ÀÇ ¼ö´Â ±Þ°ÝÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
  • ´Ù¾çÇÑ ³í¹®ÀÌ in-vitro µð½ºÇ÷¹ÀÌ ±â¼ú°ú ¹æ´ëÇÑ ºÐÀÚ ºÐ¸®¸¦ À§ÇÑ ´ë±Ô¸ð ¶óÀ̺귯¸®ÀÇ »ç¿ë¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. °Ô´Ù°¡ ÀÌ·¯ÇÑ ±â¼úÀº ÁÖ·Î Ä¡·á³ª Áø´Ü ¿ëµµ·Î »ç¿ëÇÏ´Â À¯¸ÁÇÑ ¸®µå È常¦ µ¿Á¤ÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î Çϰí ÀÖ½À´Ï´Ù.
  • ÆÄÁö µð½ºÇ÷¹ÀÌ À̿ܿ¡µµ, È¿¸ð µð½ºÇ÷¹À̳ª ¼¼Æ÷ Ç¥¸é µð½ºÇ÷¹ÀÌ µîÀÇ µð½ºÇ÷¹ÀÌ ±â¼úµµ ´Ù¾çÇÑ Ä¡·á¿ë ºÐÀÚÀÇ »ý¼ºÀ» À§ÇØ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù.
  • µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸®¿Í °ü·ÃµÈ ÁöÀûÀç»êµµ ±ÞÁõÇϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ±â¼ú°ú °ü·ÃµÈ ¼ö¸¹Àº ƯÇã(-30,000°ÇÀÇ Æ¯ÇãÃâ¿ø)°¡ ¼¼°è ¿©·¯ Á¶Á÷¿¡ Ãâ¿øµÇ¾î ºÎ¿©µÇ°í ÀÖ½À´Ï´Ù.
  • ÃÖ±Ù Ãâ¿øµÈ ƯÇãÀÇ ¼ö°¡ ¸¹À½¿¡µµ ºÒ±¸Çϰí(µû¶ó¼­ ƯÇãÀÇ ÀÜÁ¸±â°£ÀÌ ±ä), »ó´ëÀûÀÎ Æò°¡°¡ °¡Àå ³ôÀº ƯÇã´Â ÀüüÀÇ ºÒ°ú 0.21%ÀÔ´Ï´Ù.
  • ƯÈ÷ ÆÄÁö µð½ºÇ÷¹ÀÌ Á¢±Ù¹ýÀº ¸¹Àº ½ÂÀÎ ¾à¹°À» ¹ß°ßÇϴµ¥ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. »ç½Ç ½ÃÀå¿¡¼­ °¡Àå ¸¹ÀÌ ÆÈ¸®´Â »ý¹° Á¦Á¦ Áß ÇϳªÀÎ È޹̶ó(R)´Â °°Àº ±â¼úÀ» »ç¿ëÇØ ¹ß°ßµÆ½À´Ï´Ù.
  • ½ÃÀåÀº ¿¬À² 13.4%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹ÃøµÇ´Â ±âȸ´Â ´Ù¾çÇÑ µð½ºÇ÷¹ÀÌ ±â¼ú, ºÐÀÚ À¯Çüº°, ÁÖ¿ä Áö¸®Àû Áö¿ª¿¡ ºÐ»êµÇ¾î ÀÖ´Ù°í »ý°¢µË´Ï´Ù.
Drug Discovery Platforms Market-IMG3

Drug Discovery Ç÷§Æû ½ÃÀå ÁøÃâ±â¾÷ ¿¹

  • Abzena
  • Creative Biolabs
  • Distributed Bio(Subsidiary of Charles River)
  • ImmunoPrecise Antibodies
  • IONTAS
  • LakePharma
  • Leading Biology
  • Sino Biological
  • XOMA

º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ Drug Discovery Ç÷§Æû ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú À¯Çüº°, ºÐÀÚ À¯Çüº° µ¿Çâ, Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼­¹®

  • ÀåÀÇ °³¿ä
  • µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú °³¿ä
  • µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸®ÀÇ À¯Çü
  • µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸®ÀÇ ¿ëµµ
  • Àå·¡ÀÇ Àü¸Á

Á¦4Àå ½ÃÀå »óȲ : ¶óÀ̺귯¸® ±â¹Ý µð½ºÇ÷¹ÀÌ ±â¼ú°ú ¼­ºñ½º-ÆÄÁö µð½ºÇ÷¹ÀÌ

  • ÀåÀÇ °³¿ä
  • µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú ¹× °ü·Ã ¼­ºñ½º : ÆÄÁö µð½ºÇ÷¹ÀÌ ½ÃÀå »óȲ
  • µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú ¹× °ü·Ã ¼­ºñ½º : ÆÄÁö µð½ºÇ÷¹ÀÌ ÁÖ¿ä ¾÷°è ÁøÃâ±â¾÷

Á¦5Àå ½ÃÀå »óȲ : µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú ¹× °ü·Ã ¼­ºñ½º-±âŸ µð½ºÇ÷¹ÀÌ ±â¼ú

  • ÀåÀÇ °³¿ä
  • µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú ¹× °ü·Ã ¼­ºñ½º : ±âŸ µð½ºÇ÷¹ÀÌ ±â¼ú ½ÃÀå »óȲ
  • µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú ¹× °ü·Ã ¼­ºñ½º : ±âŸ µð½ºÇ÷¹ÀÌ ±â¼ú ÁÖ¿ä ¾÷°è ÁøÃâ±â¾÷

Á¦6Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • ÀåÀÇ °³¿ä
  • Abzena
  • Creative Biolabs
  • Distributed Bio(Subsidiary of Charles River)
  • ImmunoPrecise Antibodies
  • IONTAS
  • LakePharma
  • Leading Biology
  • Sino Biological
  • XOMA

Á¦7Àå »ç·Ê ¿¬±¸ : ÆÄÁö µð½ºÇ÷¹ÀÌ ¹æ¹ýÀ» ÀÌ¿ëÇÏ¿© ¹ß°ßµÈ »ý¹° Á¦Á¦

  • ÀåÀÇ °³¿ä
  • ÆÄÁö µð½ºÇ÷¹À̹ýÀ» ÀÌ¿ëÇÏ¿© ¹ß°ßµÈ »ý¹° Á¦Á¦
  • ÆÄÁö µð½ºÇ÷¹À̹ýÀ» ÀÌ¿ëÇÏ¿© ¹ß°ßµÈ »ý¹° Á¦Á¦ : °³¿ä
    • Humira(R)(Adalimumab)
    • Tremfya(R)(Guselkumab)
    • Takhzyro(R)(Lanadelumab)
    • Xyntha(R)
    • Portrazza(TM)(Necitumumab)
  • °á·Ð

Á¦8Àå ÆÄÆ®³Ê½Ê ¹× Çù¾÷

  • ÀåÀÇ °³¿ä
  • ÆÄÆ®³Ê½Ê ¸ðµ¨
  • µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú ¹× °ü·Ã ¼­ºñ½º : ÃÖ±ÙÀÇ ÆÄÆ®³Ê½Ê ¹× Çù¾÷

Á¦9Àå ÃâÆÇ¹° ºÐ¼®

Á¦10Àå Æ¯Ç㠺м®

  • ÀåÀÇ °³¿ä
  • ¹üÀ§ ¹× Á¶»ç ¹æ¹ý
  • µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú : ƯÇ㠺м®

Á¦11Àå ½ÃÀå ±Ô¸ðÀÇ Æò°¡ ¹× ±âȸ ºÐ¼®

  • ÀåÀÇ °³¿ä
  • ÁÖ¿ä ÀüÁ¦¿Í ¿¹Ãø Á¶»ç ¹æ¹ý
  • ¼¼°èÀÇ µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú ½ÃÀå : È÷Æ® »ý¼º ¼­ºñ½º(-2035³â)
  • µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú ¹× °ü·Ã ¼­ºñ½º ½ÃÀå(-2035³â) : µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú À¯Çüº°
  • µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú ¹× °ü·Ã ¼­ºñ½º ½ÃÀå(-2035³â) : ºÐÀÚ À¯Çüº°
  • µð½ºÇ÷¹ÀÌ ¶óÀ̺귯¸® ±â¼ú ¹× °ü·Ã ¼­ºñ½º ½ÃÀå(-2035³â) : Áö¿ªº°

Á¦12Àå °á·Ð

Á¦13Àå ÁÖ¿ä ÀλçÀÌÆ®

Á¦14Àå ºÎ·Ï 1 : Ç¥ Çü½Ä µ¥ÀÌÅÍ

Á¦15Àå ºÎ·Ï 2 : ±â¾÷ ¹× ´Üü À϶÷

AJY

GLOBAL DRUG DISCOVERY PLATFORMS MARKET: OVERVIEW

As per Roots Analysis, the global drug discovery platforms market valued at USD 139 million in the current year is anticipated to grow at a CAGR of 13.4% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Display Library Technology

  • Phage Display
  • Yeast Display
  • Others

Type of Molecule

  • Antibodies
  • Peptides
  • Others

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific

GLOBAL DRUG DISCOVERY PLATFORMS MARKET: GROWTH AND TRENDS

Drug discovery has always been a time-consuming process. In fact, on average, it takes 10-15 years and investments worth USD 4-10 billion to commercially launch a drug. The process of drug discovery involves various steps including, target selection and validation, hit generation, lead optimization and characterization of protocols. Of these steps, hit (potential drug candidates against validated biological targets) generation is an extremely resource-intensive process. It is worth mentioning that on average approximately 18 months is spent generating hits against a validated target. In addition to this, there is an around 25% chance of failure in the hit generation to lead identification phase of drug discovery. In order to address these concerns, developers are shifting their focus from traditional techniques to the use of novel discovery platforms.

Drug Discovery Platforms Market - IMG1

Over the years, numerous methods and approaches have been established for generating viable therapeutic leads. These include hybridoma technology, B-cell cloning, transgenic animal-based techniques, in vitro display methods and cell surface display techniques involving mammalian, yeast, and bacterial cells. In modern medical research, display libraries have been effectively utilized to generate a range of novel therapeutics and present several advantages over traditional drug screening methods. These benefits include enabling large-scale, high-throughput screening, introducing greater diversity in identifying viable leads, and reducing the risk of immune responses to pharmacological candidates discovered through this approach. Gradually, display technologies have driven significant advancements in the drug discovery process. As a result, we anticipate that the market for drug discovery platforms will experience robust growth over the forecast period.

GLOBAL DRUG DISCOVERY PLATFORMS MARKET: KEY INSIGHTS

The report delves into the current state of global drug discovery platforms market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Several companies, based in different regions of the world, claim to have proprietary display library technologies and offer affiliated services for the discovery of various types of pharmacological molecules.
  • Phage display (~70%) is considered as one of the most successful display technologies; stakeholders are also investigating several other similar approaches, such as those based on yeast and mammalian cells.
  • Display technologies offer several advantages, including large scale production, direct access to sequence and the ease of screening a large diversity of clones.
  • Display libraries can be used for in vitro selection of antibodies on immobilized antigens and isolation of antibodies against poorly immunogenic targets.
  • Some players use multiple animal models for selection that can be manipulated under the control of the animal's immune system to generate drug candidates.
  • The growing interest in this field is evident from the rise in partnership activity; in fact, the maximum number of collaborations involving various types of display library technologies were inked in the past two years.
Drug Discovery Platforms Market - IMG2
  • Both established players, as well as start-ups, have forged multiple partnerships; most of these are licensing agreements (~45%) for the technologies that can be used in research and therapeutic purposes.
  • There has been a notable increase in published scientific literature related to the different types of in vitro display libraries and enabling technologies, and approaches describing their use in the discovery of drugs / therapies.
  • In the past two years, there has been an exponential increase in the number of publications, including research articles focused on display library technologies and their applications in drug discovery.
  • Various articles focus on in-vitro-display technologies and the use of large libraries for the isolation of vast range of molecules. Further, these technologies are primarily aimed at identifying promising lead candidates for use in therapeutic or diagnostic applications.
  • Apart from phage display, other display technologies, such as yeast display and cell surface display are also being investigated for the generation of various therapeutic molecules.
  • The intellectual property associated with display libraries has also witnessed a surge, as numerous patents (~30,000 patent applications) related to these technologies have been filed / granted to several organizations across the globe.
  • Despite the large number of patents that have been filed recently (and hence having a long remaining patent life), only 0.21% of the total patents have the highest relative valuation.
  • Specifically, the phage display approach has been widely used for the discovery of a number of approved drugs; in fact, HUMIRA(R), one of the best-selling biologics in the market, was discovered using the same technology.
  • The market is projected to grow at an annualized rate of ~13.4%; the forecasted opportunity is likely to be distributed across various display technologies, types of molecules, and key geographical regions.
Drug Discovery Platforms Market - IMG3

Example Players in the Drug Discovery Platforms Market

  • Abzena
  • Creative Biolabs
  • Distributed Bio (Subsidiary of Charles River)
  • ImmunoPrecise Antibodies
  • IONTAS
  • LakePharma
  • Leading Biology
  • Sino Biological
  • XOMA

PRIMARY RESEARCH OVERVIEW

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews conducted with the following industry stakeholders:

  • Chief Scientific Officer / Founder and Chief Executive Officer / Founder, Company A
  • Chief Executive Officer / General Manager, Company B
  • President and Chief Executive Officer, Company C
  • General Manager, Company D

GLOBAL DRUG DISCOVERY PLATFORMS MARKET

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global drug discovery platforms market, focusing on key market segments, including [A] type of display library technology, [B] type of molecule and [C] key geographical regions.
  • Market Landscape: A comprehensive evaluation of the display library technologies and affiliated services market, considering various parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of company, [E] display library expertise, [F] type of molecules, [G] type and format of antibodies generated, [H] library size / complexity and [I] other services offered.
  • Company Profiles: In-depth profiles of companies offering display library technologies, focusing on [A] company overview, [B] proprietary technology and [C] recent developments and an informed future outlook.
  • Case Study: A detailed discussion of biologics discovered using phage display method along with analysis, based on various parameters, such as [A] first launch year, [B] target gene / antigen, [C] disease indication, [D] target therapeutic area and [E] revenues generated.
  • Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in this domain, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] focus area, [D] type of partner, [E] most active players (in terms of the number of partnerships signed) and [F] geographical distribution of partnership activity.
  • Publication Analysis: A comprehensive analysis of close to 2,000 peer-reviewed scientific articles related to research on display libraries, based on [A] year of publication, [B] focus area, [C] type of molecule, [D] popular keywords and [E] key journals.
  • Patent Analysis: An in-depth analysis of patents filed / granted for display library technologies, based on various relevant parameters, such as [A] publication year, [B] geography, [C] CPC symbols, [D] emerging focus areas, [E] type of applicant, [F] leading industry players and [G] patent valuation analysis.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
    • 1.2.1. Research Assumptions
    • 1.2.2. Project Methodology
    • 1.2.3. Forecast Methodology
    • 1.2.4. Robust Quality Control
    • 1.2.5. Key Considerations
      • 1.2.5.1. Demographics
      • 1.2.5.2. Economic Factors
      • 1.2.5.3. Government Regulations
      • 1.2.5.4. Supply Chain
      • 1.2.5.5. COVID Impact / Related Factors
      • 1.2.5.6. Market Access
      • 1.2.5.7. Healthcare Policies
      • 1.2.5.8. Industry Consolidation
  • 1.3 Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Display Library Technologies
  • 3.3. Types of Display Libraries
    • 3.3.1. In Vitro Display Technologies
      • 3.3.1.1. Phage Display
        • 3.3.1.1.1. Classification of Phage Display Libraries
        • 3.3.1.1.2. Applications of Phage Display Libraries
      • 3.3.1.2. Ribosomal Display Library
      • 3.3.1.3. mRNA Display Library
      • 3.3.1.4. cDNA Display Library
    • 3.3.2. Cell Surface Display Technologies
      • 3.3.2.1. Bacterial Display Library
      • 3.3.2.2. Yeast Display Library
      • 3.3.2.3. Mammalian Cell-based Display Libraries
  • 3.4. Applications of Display Libraries
  • 3.5. Future Perspectives

4. MARKET LANDSCAPE: LIBRARY-BASED DISPLAY TECHNOLOGIES AND SERVICES (FOCUS ON PHAGE DISPLAY)

  • 4.1. Chapter Overview
  • 4.2. Display Library Technologies and Affiliated Services (Focus on Phage Display): Overall Market Landscape
    • 4.2.1. Analysis by Type of Molecule Discovered
    • 4.2.2. Analysis by Type of Antibodies Generated
    • 4.2.3. Analysis by Type of Library
    • 4.2.4. Analysis by Library Size / Complexity
    • 4.2.5. Analysis by Source Organism
    • 4.2.6. Analysis by Types of Services Offered
  • 4.3. Display Library Technologies and Affiliated Services (Focus on Phage Display): Key Industry Players
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Type of Company
    • 4.3.4. Analysis by Location of Headquarters

5. MARKET LANDSCAPE: DISPLAY LIBRARY TECHNOLOGIES AND AFFILIATED SERVICES (FOCUS ON OTHER DISPLAY TECHNOLOGIES)

  • 5.1. Chapter Overview
  • 5.2. Display Library Technologies and Affiliated Services (Focus on Other Display Technologies): Overall Market Landscape
    • 5.2.1. Analysis by Type of Technology
    • 5.2.2. Analysis by Type of Molecule Discovered
    • 5.2.3. Analysis by Type of Antibodies Generated
    • 5.2.4. Analysis by Type of Library
    • 5.2.5. Analysis by Library Size / Complexity
    • 5.2.6. Analysis by Source Organism
    • 5.2.7. Analysis by Types of Services Offered
  • 5.3. Display Library Technologies and Affiliated Services (Focus on Other Display Technologies): Key Industry Players
    • 5.3.1. Analysis by Year of Establishment
    • 5.3.2. Analysis by Company Size
    • 5.3.3. Analysis by Type of Company
    • 5.3.4. Analysis by Location of Headquarters

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Abzena
    • 6.2.1. Company Overview
    • 6.2.2. Technology Portfolio
    • 6.2.3. Recent Developments and Future Outlook
  • 6.3. Creative Biolabs
    • 6.3.1. Company overview
    • 6.3.2. Technology Portfolio
    • 6.3.3. Service Portfolio
    • 6.3.4. Recent Developments and Future Outlook
  • 6.4. Distributed Bio (Subsidiary of Charles River)
    • 6.4.1. Company Overview
    • 6.4.2. Technology Portfolio
      • 6.4.2.1. Recent Developments and Future Outlook
  • 6.5. ImmunoPrecise Antibodies
    • 6.5.1. Company Overview
    • 6.5.2. Technology Portfolio
    • 6.5.3. Service Portfolio
    • 6.5.4. Recent Developments and Future Outlook
  • 6.6. IONTAS
    • 6.6.1. Company Overview
    • 6.6.2. Technology Portfolio
    • 6.6.3. Service Portfolio
    • 6.6.4. Recent Developments and Future Outlook
  • 6.7. LakePharma
    • 6.7.1. Company Overview
    • 6.7.2. Technology Portfolio
    • 6.7.3. Service Portfolio
    • 6.7.4. Recent Developments and Future Outlook
  • 6.8. Leading Biology
    • 6.8.1. Company overview
    • 6.8.2. Technology Portfolio
    • 6.8.3. Service Portfolio
    • 6.8.4. Recent Developments and Future Outlook
  • 6.9. Sino Biological
    • 6.9.1. Company Overview
    • 6.9.2. Technology Portfolio
    • 6.9.3. Service Portfolio
    • 6.9.4. Recent Developments and Future Outlook
  • 6.10. XOMA
    • 6.10.1. Company Overview
    • 6.10.2. Technology Portfolio
    • 6.10.3. Recent Developments and Future Outlook

7. CASE STUDY: BIOLOGICS DISCOVERED USING PHAGE DISPLAY METHOD

  • 7.1. Chapter Overview
  • 7.2. Biologics Discovered Using the Phage Display Method
    • 7.2.1. Analysis by Year of Launch
    • 7.2.2. Analysis by Target Antigen / Gene
    • 7.2.3. Analysis by Target Disease Indication and Therapeutic Area
    • 7.2.4. Analysis by Revenues Generated (2020)
  • 7.3. Biologics Discovered Using Phage Display Method: Brief Profiles
    • 7.3.1. Humira(R) (Adalimumab)
      • 7.3.1.1. Drug Overview
      • 7.3.1.2. Discovery Process and Method
    • 7.3.2. Tremfya(R) (Guselkumab)
      • 7.3.2.1. Drug Overview
      • 7.3.2.2. Discovery Process and Method
    • 7.3.3. Takhzyro(R) (Lanadelumab)
      • 7.3.3.1. Drug Overview
      • 7.3.3.2. Discovery Process and Method
    • 7.3.4. Xyntha(R)
      • 7.3.4.1. Drug Overview
      • 7.3.4.2. Discovery Process and Method
    • 7.3.5. Portrazza(TM) (Necitumumab)
      • 7.3.5.1. Drug Overview
      • 7.3.5.2. Discovery Process and Method
  • 7.4. Concluding Remarks

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Display Library Technologies and Affiliated Services: Recent Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Focus of Partnership (Type of Molecule)
    • 8.3.4. Analysis by Focus of Partnership (Target Therapeutic Area)
    • 8.3.5. Analysis by Type of Partner
    • 8.3.6. Most Active Players: Analysis by Number of Partnerships
    • 8.3.7. Analysis by Geography
      • 8.3.7.1. Intercontinental and Intracontinental Agreements

9. PUBLICATION ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Analysis by Year of Publication
  • 9.4. Analysis by Focus Area (Type of Technology)
  • 9.5. Analysis by Focus Area (Type of Molecule)
  • 9.6. Word Cloud: Analysis of Study Titles
  • 9.7. Key Journals: Analysis by Number of Publications

10. PATENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Display Library Technologies: Patent Analysis
    • 10.3.1. Analysis by Publication Year
    • 10.3.2. Analysis by Geography
    • 10.3.3. Analysis by CPC Symbols
    • 10.3.4. Emerging Focus Areas (Word Cloud)
    • 10.3.5. Analysis by Type of Applicant
    • 10.3.6. Leading Players: Analysis by Number of Patents
    • 10.3.7. Leading Players: International Patents
    • 10.3.8. Display Library Technologies: Patent Valuation Analysis

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Key assumptions and Forecast Methodology
  • 11.3. Global Display Library Technologies Market (Focus on Hit Generation Services), Till 2035
  • 11.4. Display Library Technologies and Affiliated Services Market, Till 2035: Distribution by Type of Display Library Technology
  • 11.5. Display Library Technologies and Affiliated Services Market, Till 2035: Distribution by Type of Molecule
  • 11.6. Display Library Technologies and Affiliated Services Market, Till 2035: Distribution by Geography
    • 11.6.1. Display Library Technologies and Affiliated Services Market Opportunity in North America Across Key Market Segments, Till 2035
      • 11.6.1.1. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Distribution by Type of Technology
        • 11.6.1.1.1 Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Phage Display Technology
        • 11.6.1.1.2. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Yeast Display Technology
        • 11.6.1.1.3. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Other Display Technologies
      • 11.6.1.2. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Distribution by Type of Molecule
        • 11.6.1.2.1. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Antibodies
        • 11.6.1.2.2. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Peptides
        • 11.6.1.2.3. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Other Molecules
    • 11.6.2. Display Library Technologies and Affiliated Services Market Opportunity in Europe Across Key Market Segments, Till 2035
      • 11.6.2.1. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Distribution by Type of Technology
        • 11.6.2.1.1 Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Phage Display Technology
        • 11.6.2.1.2. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Yeast Display Technology
        • 11.6.2.1.3. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Other Display Technologies
      • 11.6.2.2. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Distribution by Type of Molecule
        • 11.6.2.2.1. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Antibodies
        • 11.6.2.2.2. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Peptides
        • 11.6.2.2.3. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Other Molecules
    • 11.6.3. Display Library Technologies and Affiliated Services Market Opportunity in Asia-Pacific Across Key Market Segments, Till 2035
      • 11.6.3.1. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Distribution by Type of Technology
        • 11.6.3.1.1 Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Phage Display Technology
        • 11.6.3.1.2. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Yeast Display Technology
        • 11.6.3.1.3. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Other Display Technologies
      • 11.6.3.2. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Distribution by Type of Molecule
        • 11.6.3.2.1. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Antibodies
        • 11.6.3.2.2. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Peptides
        • 11.6.3.2.3. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Other Molecules

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

  • 13.1. Chapter Overview
  • 13.2. Company A
    • 13.2.1. Company Snapshot
    • 13.2.2. Interview Transcript: CSO / Founder and CEO / Founder
  • 13.3. Company B
    • 13.3.1. Company Snapshot
    • 13.3.2. Interview Transcript: CEO / General Manager
  • 13.4. Company C
    • 13.4.1. Company Snapshot
    • 13.4.2. Interview Transcript: President and CEO
  • 13.5. Company D
    • 13.5.1. Company Snapshot
    • 13.5.2. Interview Transcript: General Manager

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦